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A contemporary definition of the term immunity would be "all those 
physiological mechanisms which endow the animal with the capacity to 
recognize materials as foreign to itself and to neutralize, eliminate 
or metabolize them with or without injury to its own tissues" (7). 
The responses of immunity may be classified into two categories: 
nonspecific immunologic responses and specific immunologic responses. 
Specific immune responses depend on prior exposure to an antigen and 
the subsequent recognition of and reaction to it. On the other hand, 
nonspecific responses occur following initial and subsequent exposure 
to an antigen, and while selective in differentiating "self" from "non-
self", are not dependent upon specific recognition (7). These immuno-
logic responses serve three major functions: defense, homeostasis and 
s~rveillance. The first is involved in resistance to infection by 
microorganisms, the second, in removal of effete (worn out) self com-
ponents, and the third, with the detection and destruction of mutant 
cells. Failure of surveillance, which recognizes abnormal cell types 
which constantly arise within the body either spontaneously or induced 
by certain viruses and chemicals, has been assigned a causal role in the 




Lymphocytes are fairly small (5-15 um diameter), round,.nonde-
script cells that are -ubiquetous in blood, lymph and connective tissues. 
The two fundamentally different kinds, B and T cells, differ in origin, 
in surface macromolecules, in circulation patterns, and above all, in 
the mode and consequences of their interaction with antigens (17). 
Besides circulating through blood, lymph, and tissue spaces, 
lymphocytes are aggregated into primary and secondary lymphatic struc-
tures, where different stages in their differentiation are carried out. 
In the primary organs (thymus, bursa of Fabricius or its analog in non-
avian species) lymphocytes become committed to react specifically with 
particular antigens, and in the secondary lymphatic organs the committed 
cells react with antigens, which stimulate their terminal differentia-
tion with different functions. The B cells differentiate into antibody-
secreting plasma cells, and T cells become effectors of cell-mediated 
immunity; also, both cell types differentiate into their respective mem-
ory cells (17). 
Specific Immunity 
The specific immune responses are concerned with the recognition 
of foreign traits in a highly discriminatory way. Results of the sub-
sequent reaction between host and foreign configuration depend on 
properties of the substance (size, structure, amount) and also on the 
properties of the host (age, genetic make up) (7). The specific immune 
response is the host's subsequent reaction to a foreign substance and 
encompasses a series of cellular interactions expressed by the elabor-
ation of specific cell products. There are three general characteristics 
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of the specific immune response which distinguish it from the nonspecif-
ic response: specificity, heterogeneity and memory. I' 
Specificity is the highly discriminatory selectivity with which 
the products of the immune response will react solely with the config-
uration identical or similar to that which caused the i-nitial response • 
(7). Nonspecific responses represent the initial encounter with for-
eign traits, which upon subsequent encounter merely repeat the same 
general response to that substance. Therefore, they lack specificity. 
Specificity is the character of the immune response which distinguishes 
one antigen from another (7). 
The second characteristic of the immune response is heterogeneity, 
in which a wide array of cell types and cell products are induced to 
interact with a diversity of responses with the variety of cell types. 
Unlike the nonspecific response of phagocytosis in which there is a 
limited number of pre-existent cell types, the specific responses are 
characterized by the induction and interaction of a variety of new cell 
types specific for the inducing antigen (7). Heterogeneity of the cell 
types, T and B cells, gives rise to elaboration of an equally hetero-
geneous population of cell products. This heterogeneity of antibody 
contributes a fine degree of homeostatic control with which the host 
may respond in a highly variable and specific manner with foreign 
structures ( 7) • 
The third property of the specific immune response is that of 
anamnestic response or memory. Memory results in augmentation of the 
response through proliferation and differentiation of cells upon sub-
sequent exposure to an immunogen. This leads to an increased elabora-
tion of cell products. The nonspecific immune responses do not include 
4 
the property of memory (7). 
The lymphoid cells of the immune system have the ability to react 
specifically with antigens and to elaborate specific cell products. 
The lymphoid cells include plasma cells and lymphocytes. These cells, 
once sensitized, become "committed" and are referred to as immunocytes. 
The two main fUnctions of lymphocytes are antibody production and cell-
mediated interactions, as directed by thymic-independent and thymic-
dependent influences, respectively. It is believed that the thymus 
influence leads to the production of cells equipped to handle cell-
mediated events. The lymphocytes considered to be thymic-jndependent, 
and whose known function is concerned with antibody synthesis are also 
part of the recirculating pool of lymphocytes. 
Mature B plasma cells have been shown to store and release antibody 
and are believed to be of primary importance in antibody synthesis. 
While the B cell lymphocyte is involved in antibody synthesis, the T 
cell produces a variety of factors which trigger inflammatory or cell-
damaging reactions leading to cell-mediated events. These factors 
I 
include the migration inhibitory factor (MIF), a cytotoxic factor cap-
able of injuring a variety of cell types, interferon and several other 
factors whose biological roles are not yet well defined. Some are re-
leased upon interaction of sensitized B lymphocytes with appropriate 
antigens; others may remain cell-bound. In either case, they lead to 
the destruction of foreign target cells or to the damage and destruction 
of host tissues. Thus, it is apparent that the lymphocytes possess the 
most diversified function of all cells of the immune system (7). 
The induction of antibody formation by many immunogens requires 
specific interaction with both B and T cells, with the T cells somehow 
regulating the proliferation and differentiation of B cells into anti-
body-secreting plasma cells {17). 
5 
Studies have shown that the active cells in bone marrow and thy-
mus are precursors of B and T cells, respectively, and that the anti-
body-secreting cells are derived from the marrow and not from the 
thymus cells {17). B and T lymphocytes look alike and both are mobile, 
nonphagocytic cells of varying size. 
Specific binding of antigen by membrane-bound receptors on the cell 
surface can stimulate transformation of small B cell lymphocytes into 
larger ones whose more abundant cytoplasm contains endoplasmic reticulum 
and a prominent Golgi apparatus, and is richer in mitochondria and poly-
somes. In accordance with the appearance of a secretory system (endo-
plasmic reticulum, Golgi apparatus) some of the large lymphocytes of B 
type secrete antibodies. The large cells also divide more rapidly and 
some of those of B lineage differentiate into mature plasma cells, the 
most active of all lymphoid cells in synthesis and secretion of immuno-
globulins. Many large lymphocytes also revert back eventually into 
small ones, which probably function as "memory cells". Small lymphocytes 
(except for a few exceptions) rarely divide unless stimulated by antigen 
(17). 
Transplantation experiments in chickens have shown that B cells 
arise from migrant bone marrow stem cells (primitive precursors of 
hematopoietic and lymphoid cells) that lodge in the bursa of Fabricius 
where they begin to synthesize immunoglobulins. In mammals, which lack 
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a bursa, it is not certain where the B cell precursors become committed 
to synthesize a particular immunoglobulin. This could happen in the 
bone marrow itself or in lymph nodes or lymphoid structures, such as 
the tonsils or appendix (17). 
T lymphocytes also originate from bone marrow stem cells, which 
migrate to the thymus where they divide rapidly. Most of the rapidly 
dividing cells die without leaving the thymus. The survivors, mature 
T cells, differ from entering stem cells in several important properties 
that are acquired in the thymus, or possibly in other tissues under 
direction of a thymus hormone. They develop characteristic surface 
antigens. They can react specifically with one or a few antigens and 
they become antigen-sensitive (immunologically committed) lymphocytes. 
Besides acquiring the capacity to regulate B cell responses to antigens, 
specifically reactive T lymphocytes can become specific effector cells 
for cell-mediated immune responses. They can destroy tumor cells, cause 
rejection of allografts, and promote the differentiation of resting 
macrophages into highly bacteriocidal cells capable of destroying bacter-
ial pathogens. T cells are heterogeneous and it is likely that T cell 
effectors of cell-mediated immune reactions differ from those that reg-
ulate the differentiation of B cells into antibody-secreting cells (17). 
T cells exercise their effects both through contact with B cells 
and the release of diffusible factors that act at short range on nearby 
B cells. Thus T cells can aid B cells when they react at the same time 
and in the same locale. The highest antibody yields are obtained when 
cooperating B and T cells are specific for determinants on the same 
immunogenic particle. There seem to be two diffusible factors: a low-
molecular-weight (dialyzable) nonspecific substance that enhances the 
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response of B cells of any specificity and a high-molecular-weight (non-
/ 
\ 
dialyzable) specific factor that augments only those B cells that can 
react specifically with the same immunogen that activated the T cells 
release of the factor (17). 
Though T cells exercise an important regulatory role on responses 
I 
of B cells to T-dependent immunogens, it is important to note that anti-
gens can induce B cells, in the absence ofT cells, to make antibodies 
of the IgM class, and to differentiate into memory cells whose response 
to a subsequent introduction of the immunogen elicits the augmented 
secondary response. However, the further maturation of the primary 
response, usually characterized by the production of IgG antibodies, 
seems not to occur unless T cells are engaged (17). With antigens 
whose induction of antibody synthesis in primary spleen cell culture 
requires accessory T cells, there is a further requirement for adherent 
cells, probably macrophages, and a complex of B and T cells bind to the 
antigen on the sticky surface of the macrophage. While each of the 
cooperating B and T cells react specifically with an antigenic determin-
ant of the immunogen, the macrophages act nonspecifically (17). 
Antibodies combat the antigens in one of several ways. They may 
combine with the antigen and complement and neutralize them; they may 
cause the invading microorganism to break up and dissolve (a phenomenon 
known as lysis); or they may make the invaders more susceptible to 
phagocytosis (63). 
~e two effector mechanisms which mediate specific immune responses 
are those mediated by a cell product of the lymphoid tissues referred 
to as antibody (humoral immunity) and those mediated by specifically 
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sensitized lymphocytes themselves (cell-mediated immunity or delayed 
hypersensi ti vi ty) . Anti body is the product of the lymphoid series which 
is either cell-bound or secreted as an extracellular product. It has 
the capability of reacting with the configuration respons~ble for its 
production (7). The cell-mediated response is the second major effector 
mechanism underlying specific immunity. It is recognized to be a re-
sponse important in recovery from many infectious diseases and important 
in surveillance against neoplasms (7). The effector mechanism seems 
to be monitored by the thymus and mediated by the thymic-dependent pro-
cesses (7). Cell-mediated reactions are initiated by the recognition of 
antigen by the cell surface receptor on the lymphocyte. The morphologic 
changes of lymphocytes consist of blast cell formatfon and subsequent 
mitosis. Several agents have been known to induce these changes (mite-
gens, Bacillus Calmette Guerin (BCG), Corynebacterium parvum, tumors 
invading an organism, antibodies against foreign structures) (7, 8, 21, 
35, 50, 67). 
Nonspecific Immunity 
Nonspecific immunity involves an inflammatory response and phago-
cytosis (7). The first encounter of the host with a foreign config~a­
tion leads to a stereotyped response. This consists of the mobilization 
of phagocytic elements into areas that a foreign configuration has been 
introduced. This can occur as an isolated event or as a part of the 
inflammatory response (7). Once mobilized, the phagocytic cells mount 
an attack on their target by a process called phagocytosis. It requires 
recognition of the material to be ingested, movement toward the object 
(chemotaxis), and ingestion and subsequent intracellular digestion by 
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lysosomal products. It includes utilization of humoral antibodies (op-
sonins) and enhancement of intracellular metabolic events. 
Following injury or invasion, systemic events are also triggered, 
which involve fever and a series of hematologic phenomenon (7). 
Twnor Immunity 
The host possesses both specific and nonspecific mechanisms of 
response to tumor formation. In tumor rejection, as in protection from 
infecting agents, the host immune response is directed toward the main-
tanence of homeostasis, the tendency to maintain uniformity or stability 
in the internal environment of the organism. This homeostasis may be 
altered toward the establishment of the tumor or in favor of the host 
(7). Most investigators believe that the host's immune system plays a 
major role in the defense against neoplasms (10, 12, 14, 24, 25, 29, 52, 
53). The immunogenicity of the cell surface is extremely complex because 
of the large number of expressed and potentially expressed antigenic de-
terminants (14). 
Surgery, radiotherapy and chemotherapy are all vital techniques 
required to reduce tumor burden, but none of these has the sufficient 
specificity to recognize and discriminately destroy widely distributed 
metastatic cells. 
Infection of a newborn animal with DNA or RNA viruses may lead to 
development of tumors because of immunologic immaturity of the newborn 
(7). Such nonspecific factors as phagocytosis, chemotaxis, and the in-
flammatory response are incompletely developed in the young host (7). 
The fundamental role of cell-mediated immunity is clearly shown by 
the ability to transfer a tumor immune response from an immune to a 
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nonimmune animal by adoptive transfer of lymphoid cells. Also, mixing 
tumor cells in vitro with sensitized lymphocytes leads to the destruc-
tion of tumor cells by the lymphocytes. Thymectomized animals, patients 
with thymic-dependent immunologic deficiencies and patients who have 
been immunosuppressed, all show an increased incidence of malignancy (6). 
In patients with Burkitt's lymphoma and malignant melanoma, a loss of 
tumor-specific cell-mediated immunity has been demonstrated in those who 
were in the active phase of disease. After removal of these malignan-
cies, there was a corresponding return of tumor-specific delayed hyper-
sensitivity (7). Cell-mediated immunity is a primary response to tumor 
antigens. Cell-mediated immunity is the prime mode of destruction of 
tumor cells (7, 9, 10). 
The distribution and concentration of antigens found on the tumor 
cell surfaces vary with the type of tumor (7). There appears to be a 
relationship between the relative concentration of antigen and the re-
sponsiveness of tumor tissue to antibody (7). 
Tumor-specific antibodies, in the presence of complement, lyse 
tumor cells by perforation of the cell membrane. Most are of the IgG 
class (7, 10). However, both circulating antibodies and cell-mediated 
immunity are implicated in tumor growth and regression (9, 10). Experi-
mental evidence indicates that circulating antibodies against tumor 
antigens may play a role in prolonging tumor survival. Humoral anti-
bodies may protect cells from destruction by immune lymphoid cells by 
blocking receptor sites on target cells, which masks the antigenic sites 
to which immune B lymphocytes are directed (9). So, in some cases, 
immunization of experimental animals with tumor cells or tumor antigens 
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causes that animal to produce circulating antibodies that bJ:ock cytolytic 
effects of B lymphocytes on the tumor and allows the growth of tumor 
cells (9, 56). Cellular immunity, though~ plays the major role in the 
rejection of cancer (9, 56). Chemotherapy is not able to eradicate 
most tumors even when cytostatic drugs are given in large, toxic doses. 
Also, many patients with localized tumors relapse after, apparently 
complete surgical resection or radiotherapeutic destruction, indicating 
that these two weapons often leave residual disease. Therefore, a 
search for treatments using the host's own immune system to kill the 
last tumor cell has been promoted (37). 
Tumor immunology is one of the most promising areas of cancer re-
search. The intrinsic qualities of the immune system suggest that it 
could be more effective in combating cancer than other methods in use. 
First, it is the body's own natural defense, and second, it can reach 
all areas of the body. In instances of viral and bacterial infection, 
the immune system is responsible for the final clearing of the infective 
agents from the host. 
Tumor immunology became feasible with the demonstration that most 
tumors possess antigens not characteristic of their tissue of origin. 
These antigens are known as tumor-specific antigens (TSA) or tumor-asso-
ciated transplantation antigens (TATA) and they may or may not cross 
react with antigens of other tumors of the same type (10). Probably 
~umors caused by the same type of virus do cross-react, whereas most 
I 
chemically-induced and spontaneous tumors cannot be demonstrated to have 
cross-reacting antigens (43). 
The primary goal of immunotherapy is to use the host's immune sys-
tem to prevent manifestation of the tumor by specifically destroying all 
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neoplastic cells even though these celis are disseminated throughout the 
host's body. Evidence indicates that tumor destruction could be accom-
plished by inununization with modified tumor cells, whose surfaces have 
been altered to enhance tumor-specific inununogenicity without provoking 
autoimmune rejection of normal host tissue (54). 
In addition to the search for superior inununizing agents, one must 
also consider the immunological capabilities of the host prior to tumor 
development (normal status), during active tumor growth, and at differ-
ent times following anticancer therapy. Many aspects of the immunologi-
cal scheme are only partially resolved. The humoral and cell-mediated 
components, once believed to be separate and rather independent faculties 
of the immune system, now appear to vary in their degree of interaction 
from nearly independent activity against some types of stimulation to 
very close interdependence in reaction to other stimuli (12, 14, 24, 25, 
45). Once the tumor cell population reaches a mass of between 10~ and 
104 cells in mice, it appears to be sufficiently large to nullify those 
immunological responses of the host capable of inhibiting tumor growth 
(29). Investigators now believe that autosolubilized antigens, mostly 
of fetal origin, are released from the tumor cell. These antigens, free 
in circulation, are then able to interact with the host's lymphoid cells 
causing the loss of killer activity. These soluble antigens may also 
stimulate the production of specific inununoglobulins which apparently 
cover the tumor surface and protect it from immune destruction (14, 24, 
25). Therefore, tumor burden must be reduced below this nullifying 
level to allow immunotherapy to proceed. Surgery, radiotherapy or chem-
otherapy are therefore required to reduce tumor burden, but they must be 
13 
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timed correctly to allow the host's immune system to fully benefit from 
these treatments (38). 
When rabbit antisera prepared against extracts of gastrointestinal 
tract carcinomas are absorbed with extracts of normal intestinal mucosa, 
the residual antibodies react with an antigen (a glycoprotein with 50% 
carbohydrate; MW 1 x 105 to 2 x 105) that is present not only in gastro~ 
intestinal mucosa, liver and pancreas (which are endodermal derivatives 
of the gut). This carcinoembryonic antigen (CEA) or fetal antigen appears 
to be specified by a normal gene that is expressed transiently in endo-
dermal cells during fetal development, and in adult life if these cells 
undergo malignant change (17). 
Serum from nearly all patients with colon or rectal adenocarcinoma 
contains CEA, and many also contain antibodies to CEA. Both disappear 
with successful surgical removal of the cancer, and reappearance of CEA 
can be the first diagnostic clue to the tumor's recurrence. With wide-
spread metastases, the CEA concentration rises and anti-CEA disappears 
(masked by antigen excess). With highly sensitive radioimmunoassays 
that can detect 1 ng, CEA or a substance that cross-reacts with it has 
also been detected in sera of some persons with carcinoma of lung or 
breast. Other fetal antigens are associated with certain other human 
cancers: alpha-fetoprotein is found in serum of patients with hepatomas 
or embryonal carcinomas, ga.nuna-fetoprotein, a serum protein of fetal 
blood, is found in subjects with various types of cancer. The detection 
in adult serum of fetal antigens, by sensitive and rapid serological 
tests, promises to provide screening assays for the early detection of 
human cancers (17). 
14 
With the demonstration of antigenic differences on tumor cell 
surfaces, it was proposed that they could be used as immunizing agents 
or immunotherapeutic agents after being inactivated.· -The modified cells 
can be used alone as an immunizing agent or in conjunction with chemo-
therapy, radiation therapy, or surgery as immunotherapy. 
A number of agents have been used to alter whole tumor cells prior 
to immunization regimes. Cells can be injected into the host mixed 
with a nonspecific immune stimulant such as BCG (6, 19, 29). Treatments 
such as X-irradiation at doses sufficient to kill tumor cells (30), 
treatments with Vibrio cholera neuraminidase which cleaves sialic re-
sidues from the membrane surface (10, 29, 62), repeated freeze-thawing, 
exposure to iodoacetamide which blocks sulfhydral groups (13, 27, 42), 
and mitomycin C, an inhibitor of DNA synthesis which may or may not lead 
to membrane alterations (45, 46), can enhance tumor cell immunogenicity 
in certain tumor-host systems. These findings encourage the notion that 
efficient and effective immunizing agents do exist and can be obtained 
through suitable manipulation (37). 
Cell surface phenomena account for many of the characteristics 
observed in a developing tumor. The process of transformation changes 
the extent of cell-to-cell interactions which account for the change in 
social behavior and metastases (14). 
Even though internal cellular membranes may present antigens simi-
lar to external ones, it is the plasma membrane of the tumor cell which 
comes in contact with the immune surveillance system of the host. Also, 
the plasma membrane is thought to play an important role in processes 
such as cohesiveness and contact inhibition (42). 
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It is most likely that tumor cell membranes can be made more anti-
genic and effective immunizing agents by the enzymatic and/or chemical 
modifications simil~r t() those described for whole cells. The use of 
membranes as immunizing agents is very desirable and represents a log-
ical extension of current research efforts for several ~m:portant reasons. 
First, the cell membrane surface is that portion of the tumor cell which 
interacts with the host's immune system. Second only tumor material 
contains the specificity required for effective tumor rejection. Third, 
since the host's immune system has a finite remponse capability which 
has already been diminished by tumor burden, it should be :presented With 
the maximum quantity of surface immunogen (cell membrane) while minimiz-
ing the addition of non-surface antigen (DNA, RNA, enzymes, mitochondria, 
etc.). The immune system of a mouse is :paralyzed by administration of 
greater than 1 mg irradiated BSA :protein given 3 times a week for 3 
weeks (40). Fourth, the administration of membranes minimizes the risk 
of infecting the host with some viruses (intracellular nonmembrane-as-
sociated) or other foreign agents which reside in cells both in vivo 
and in vitro and often remain active after the cells become non-viable. 
The hypothesis was that certain modifications of whole tumor cells 
(cells treated with ZnC12 , mitomycin C, or X-irradiated cells) and iso-
lated ZnC12-treated tumor cell membranes enhance the inununo~enicity of 
these immunizing agents, and lead to the development of a more effec-
tive tumor-suecific immunotherapy agent. 
I CHAPTER II 
MATERIALS AND METHODS 
Tumor-Host System 
I 
The animal hosts used for all immunizations and used for growing 
some of the tumor cells were white mice of an outbred strain designated 
HaM/ICR (CD1 ) originally obtained from the Charles Rivers Mouse Farms, 
Wilmington, Mass. They were isolated for two weeks when received, and 
given food and tap water ad libitum. Some were retained as breeders 
and their offspring used in later experiments. The mice used in exper-
iments were at least six weeks of age. In some experiments, the ani-
mals used for growing the SA-180 cells were black BDF1 mice of both 
sexes. They were obtained from Sprague-Dawley Laboratory, Madison, Wis-
consin, and used at an age of about six weeks. The BDF1 is an inbred 
mouse strain. 
Sarcoma 180 ascites (SA-180) tumor cells originated as a carcinoma, 
a malignant tumor made up of connective tissue enclosing epithelial 
cells. It was originally grown as a solid tumor but was adapted to 
grow as an ascites cell sometime before 1919 (31). The tumor has been 
maintained at Oklahoma State University since 1965 by weekly intraper-
itoneal (i.p.) injections of approximately 1 x 105 cells in 0.1 ml of 
Hepes (N-2 hydroxyethyl piperazine-N'-2, ethane sulfonic acid) buffered 
saline (HBS) in HaM/ICR (CD1 ) mice of both sexes. After seven days, 
16 
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approximately 8 x 107 cells were recovered from the peritoneal cavity 
' 
of the mouse by aspiration, washed with HBS and used for reinjection. 
This tumor may possibly show fewer histocompatibility antigens 
than most cells·because of its ability to grow in different strains 
of mice. This is important because the histocompatibility antigens 
are usually the most strongly expressed antigens. Their absence allows 
a more detailed examination of reactions with tumor-associated and 
fetal antigens. 
Procedures for Stock Solutions 
All solutions used were made up in doubled distilled (dd) water. 
Hepes Buffered Saline (HBS) 
8.00 gms NaCl 
0.40 gms KCl 
0.10 gms Na2HPo3 
1.00 gms Dextrose 
2.30 gms Hepes 
Add H20 q.s. 1 liter (1.) 
Adjust to pH 7.4 with NaOH and autoclave or filter. 
Phosphate Buffered Saline (PBS) (pH 7.2) 
24 ml of 0.15 M KH2P04 
76 ml of 0.15 M Na2HP04 
100 ml of 0,15 M NaCl 
Autoclave or filter and store at 4° C. 
The following solutions were maintained: 0.15 M KH2P04, 0.15 M 
NaCl, 0.15 M Na2HP04. 
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l10 mM Tris (hydroxymethyl) aminometha.ne (The.m) MW 121.14 
Stock solutions of 0.1 N HCl and 0.2 M T~is were prepared. These 
were used to prepare the various tris buffer solutions. 
0.01 N HCl 0.2 M Tris 
0.05 M Tris 0.04 M (40mM) Tris 
Preparation of Two.Phase Reagent Stock Solutions 
Stock solutions of two-phase reagents {500 ml) were made of 30% 
w/w Carbowax 6000 (Applied Sciences Laboratories, Inc., State College, 
Pa.) and 20% Dextran T-500 (Pharmacia, Uppsala, SWeden) and mixed with 
0.2 M NaP04 buffer (pH 6.5) and 10 mM ZnCl2. The mixture was allowed 
to stand overnight in a separatory funnel in the cold room (4° C). 
The next morning, the upper phase and lower phase were separated into 
individual bottles, autoclaved and stored in the cold until used. 
30% Carbowax 6000 
10 mM ZnCJ2 
20! Dextran T-500 
0.2 M NaPOli Buffer (pH 6.5) 
~or this buffer 500 m1 each 
of 0.2 M Na.P04 and 0.2 M Na2P04, 
pH 6.5 are made and mixed to-
gether until pH 6.5 is reached. 
The following volumes of the various solutions were combined into 
a large beaker, mixed and allowed to settle in the cold overnight. It 
separated into two phases, a lower phase and an upper phase. 
77.4 gms 30% Carbowax 
150.0 gms 20% Dextran 
249.9 ml 0.2 M NaP04 buffer (pH 6.5) 
60.0 ml 10 mM ZnC12 
Preparation of Glycine-EDTA (Ethylenediaminetetra-
acetic Acid) and Glycine-EDTA-2, Mercaptoethanol 
Various stock solutions (5 mM glycine, 1 mM EDTA and 5 mM 2, 
I 
mercaptoethanol) were used to prepare the solution of glycine-EDTA-
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2, mercaptoethanol. The glycine-EDTA solution was made by omitting the 
2, mercaptoethanol. 
5 mM Glycine and 1 mM EDTA 
Glycine (0.375 gms) and EDTA (0.336 gms) were added to 1 liter 
water. The pH was adjusted to 8.6 with either HCl or NaOH before the 
addition of mercaptoethanol. 
5 mM 2, Mercaptoethanol 
For the solution used in the third extraction of membranes with 
EDTA, 2, mercaptoethanol (0.078 gms) was added to 1 liter of the pre-
pared glycine-EDTA solution. The solution was sterilized when used at 
room temperature. 
Isolation of SA-180 Plasma Membranes by a 
zn++ Stabilization Method 
The agent used as the immune stimulus in most of the experiments 
was SA-180 tumor cell plasma membranes isolated by a procedure described 
by Shin and Carraway (1973), using a modification of the Warren method 
(1969). (See Figure 1.) Tumor cells were collected in a laminar flow 
hood. 
Figure 1. Membrane Isolation Scheme for the SA-180 Tumor Using the 
Stabilization Technique 





Pellet - 750 rpm x 3 mih 






40 mM Tris 
Pellet - 2,000 rpm x 3 min. 
(Swollen Cells) , 
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l mM ZnC12 at 25° C for 15 min 
cool on ice for 15 min. 
zn++ Treated Cells 
Homogenize (Dounce) 
Dilute with 40 mM Tris 
Pellet - 750 rpm x 3 min 
(Nuclei, Whole Cells and Plasma Membranes) 
Supernatent 
(Plasma Membrane Enriched Fraction) 
Pellet - 2,000 rpm x 10 min 
(Plasma Membrane Enriched Fraction) 
I 
Two-Phase ~eparation - 10,000 rpm x ~5 min 
Interface Lower Phase 
(Plasma Membranes) 
Wash in 40 mM Tris 2 Times 
2,000 rpm x 10 min 
Purified Plasma Membranes 
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Washed ascites SA-180 cells from 20-25 freshly killed mice were sus-
pended in 10 volumes of cold 40 mM Tris and the cells allowed to swell 
for 3 minutes at 4° C. The swollen cells were centrifuged at 1446 g·min 
(2000 rpm x 3 min) in a Sorvall SS-34 head. This procedure hemolyzes 
erythrocytes and leaves their ghosts in the supernatant solution which 
is discarded. The pellet of swollen cells was suspended in 10 volumes 
of l mM ZnCl2 at 25° C for 15 min and cooled in an ice bucket for an 
additional 15 min in order to "harden" the cell membranes. The cell 
suspension, which appeared swollen but intact under phase contrast 
microscopy, was then homogenized in a Dounce hand homogenizer (about 
13-18 strokes) until microscopic examination revealed that most of the 
cells had been broken, the membranes were visible as sheets and intact 
envelopes and the nuclei were not ruptured. An equal volume of 40 mM 
Tris buffer was added to the homogenate solution. The homogenate was 
subjected to slow centrifugation (210 g·min) (750 rpm x 3 min) in an 
SS-34 head to spin down nuclei and whole cells. The whole cells were 
homogenized and centrifuged a second time to produce a higher yield of 
membranes. The membranes, which were left in the supernatant, were 
pelleted at 1200 g·min (2000 rpm x 10 min) in a Sorvall HB-4 head. 
The supernatant solution, which contained soluble cytoplasmic constit-
uents, was discarded. The pellet, rich in plasma membranes and contain-
ing a few contaminating nuclei, was washed once more in 10 volumes of 
40 mM Tris and centrifuged at 4820 g•min (2000 rpm x 10 min) in a 
Sorvall HB-4 head. 
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Purification by the Two-Phase Method 
The washed pellet of crude plasma membranes was purified by par-
tition between two immiscible phases composed of dextran and poly-
ethylene glycol (Carbowax 6000) polymers in a phosphate buffer with 1 
mM ZnC12 as described by Brunette and Till. The pellet was suspended 
in 4 volumes of the upper phase, mixed with 4 volumes of the lower phase 
and centrifuged at 244 Kg·min (10,000 rpm x 15 min) in a Sorvall HB-4 
swinging bucket head to separate the two phases. The interface band of 
membranes was further purified by repeating the two-phase separation. 
The interface band, composed of large plasma membrane fragments, was 
decanted into a new tube and washed twice in 4o mM Tris at 4820 g·min 
(2000 rpm x 10 min ) in a Sorvall SS-34 head. The purified membrane 
sheets were suspended in 10 ml 40 mM Tris and a Lowry protein assay 
performed to determine protein concentration (32). The membranes were 
frozen at -30° C until used. 
Protein Quantitation Determined by the 
Lowry Method 
The protein concentration of membrane or whole SA-180 cell protein 
was determined by the method of Lowry et al. (32). 
Reagents 
Falin Reagent = 50 ml Falin A+ 0.5 ml Folin B-1 + 0.5 ml Falin B-2 
Folin A = 2% Na2co3 in 0.1 N NaOH 
Folin B-1 = 2% Na Tartrate 
Folin B-2 = 1% CuS04:5 H20 
2 N Phenol Reagent 
BSA Protein Stan.dard = 500 ug/ml 
Sample Preparation for the Lowry Protein Analysis 
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Sample could be solubilized by making to 4% in SDS (16% SDS, 5 mM 
EDTA, 1 mM P04 pH 7.4) and boiling sample for 10 min with a marble on 
top to stop evaporation. The solution was cooled and samples removed. 
I 
Originally samples were solubilized, but results indicated that this 
was not necessary since the procedure itself solubilizes, and in later 
experiments it was omitted. One 5 ul, 10 ul and 20 ul samples were 
taken for the assay. All samples were made to 0.50 ml with H2o. A 
standard curve was constructed with varying amounts of standard BSA 
protein and H20 as seen in Figure 2. 
Assay Procedure 
The procedure is timed with a stopwatch to keep operations at the 
same time interval. To each tube add 2.0 ml Folin reagent. Wait 10 
min (time is critical) and add 0.100 ml 2 N Phenol reagent. Vortex 
immediately. Wait 30 min and read at Absorbance 560 nm against a 0 ug 
BSA standard as blank. 
The protein concentrations of the immunizing agents were determined 
by the Lowry method. Samples of membranes or treated whole tumor cells 
were suspended in HBS to the desired protein concentration for the in-
jections in t~e immunization scheme. 
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Immunization of CD1 Mice with zn++ Treated 
SA-180 Cell Membranes Isolated from 
Tumor Cells Grown in BDF1 Mice 
The subjects used in all immunizations were HaM/ICR (CD1 ) mice. 
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The immunization schemes used in all experiments were devised to take 
full advantage of the capacity of the host's immune system. In general, 
the scheme consisted of 2 injections (i.p.) per week for 3 weeks. The 
protein dose for the first injection was 0.4 mg protein per mouse in 
the immunized group. The 5 subsequent injections contained 0.8 mg pro-
tein per mouse. The total protein given per mouse in the immunized 
group ~as 4.4 mg. The control mice received an equivalent volume of 
HBS. This scheme was chosen to allow the immune system to develop a 
full response before the challenge dose of viable tumor was given 1 week 
after the last injection. The general immunization scheme is shown in 
Table I and a summary sheet of the immunizing agents is given in Table 
II. 
Membranes were isolated from cells grown in BDF1 mice by the Zn++ 
two-phase stabilization method. Membranes isolated in this fashion will 
hereafter be designated as ZnCl2 or zn++ treated SA-180 membranes. A 
Lowry protein assay was performed and the membranes alliquoted into one 
tube of RES-membrane solutiqn contalning 4 mg protein and 5 tubes con-
taining 8 mg protein. The immunization scheme previously described was 
followed. The 7 mice in the immunized group and the 10 mice in the con-
trol group were challenged i.p. with 1.1 x 104 viable SA-180 tumor 
cells. One month following the initial challenge, the ,survivors were 
rechallenged with 1.25 x 105 live SA-180 cells per animal and the 
TABLE I 
GENERAL IMMUNIZATION SCHEME FOR MICE WITH 
MODIFIED SA-180 TUMOR MATERIAL 
IMMUNI7.ED GROUP CONTROL GROUP 
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Immunizing Agent Hepes Buffered Saline 
0.4 mg/mouse eauivalent volume 
0.8 mg/mouse equivalent volume 
0.8 mg/mouse equivalent volume 
0.8 mg/mouse equivalent volume 
0.8 mg/mouse equivalent volume 
0.8 mg/mouse equivalent volume 
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TABLE II 







(BDF1 grown cells) 
SA-180 Membranes 
(Group 1 extracted) 
SA-180 Membranes 
(Group 2 extracted) 
SA-180 Membranes 






Membranes (Group 1) X 
Immunotherapy w/SA-180 
Membranes (Group 2) X 
Whole SA-180 zn++ 
Cells (Group 1) X 
Whole SA-180 zn++ 
Cells (Group 2) X 
Whole SA-180 zn++ X 
Cells (Group 3) 
Whole SA-180 zn++ 
Cells (Group 4) X 
Whole SA-180 zn++ 
Cells (Group 5) X 
Mitomycin C Trt Cells X 































2. 5 x 102 SA-180 inj. X 
Preceeded w/a live 
2. 0 x 102 SA-180 inj. X 
4 mg protein given 
for 1st injection X 








*All agents were given in the same schedule. The immunizing reg1m1ne 
used consisted of 0.4 mg protein per mouse for the first injection, and 
0.8 mg protein per mouse for the 5 subsequent injections. The challenme 
dose of live tumor cells was given 1 week after the last immunizing 
injection in all immunizations. For the immunotherapy groups, the 
challenge was given 24 hours before therapy began. 
30 
survival times checked. Four months following the second challenge, 
those survivors were injected with 1 x 105 viable SA-180 cells and the 
survival times noted. 
Immunization with zn++ Stabilized SA-180 Plasma 
Membranes Ex:tracted with Glycine-EDTA and 
Preliminary Evidence of Extraction with 
Glycine-EDTA-2, Mercaptoethanol 
Another experiment involved extracting zn++ stabilized SA-180 
membranes with glycine-EDTA (in immunizations 1 and 2 with glycine-EDTA 
extracted SA-180 membranes) or with glycine-EDTA-2, mercaptoethanol 
(in immunization 3 with extracted membranes). In this type of isola-
tion, small membrane vesicles are formed without the high-molecular-
weight proteins that are thought to stabilize the membranes (27). If 
the proteins on the membrane are held together by disulfide bonds, the 
2, mercaptoethanol will disrupt the bond and allow the protein to open 
up. For every mg of protein present in the isolated zn++ two-phase 
membrane pellet, 2 m1 glycine-EDTA (-2, mercaptoethanol in immunization 
group 3 with extracted membranes) solution was added. The membrane-
glycine-EDTA (-2, mercaptoethanol) solution was mixed overnight at 4° 
C. The solution was next centrifuged in an SS-34 head at 945 Kg•min 
(15 K rpm x 35 min). The pellet of extracted membranes was suspended 
in a small volume of 40. mM Tris and the protein concentration-determined 
as described earlier. The extracted membranes were alliquoted into 
concentrations for injections and the immunization scheme previously 
mentioned was followed. One week after the last injection, all mice 
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were challenged i.p. with a viable SA-180 tumor dose. The survivors 
were rechallenged one month following the initial challenge with a live 
tumor dose. In immunization 1 with EDTA-extracted membranes, the chal-
. 4 8 lenge was 1 x 10 SA-l 0 cells per animal and the rechallenge for all 
but one of the survivors was 1 x 106 live tumor pells. The one animal 
not injected with 1 x 106 cells ~as challenged with 1 x 105 tumor cells. 
For the second group of mice immunized with EDTA~extracted membranes, 
the challenge for all animals and the rechallenge for those survivors 
was 1 x 105 viable SA-180 cells. In group 3, the animals were chal~ 
lenged with 1.25 x 105 SA-180 cells per mouse. 
Immunization with zn++ Treated SA-180 Cells 
Whole cells of SA-180 from 2 freshly killed animals were washed 
free of serum and red blood cells in HBS at 210 g·min (750 rpm x 3 min 
in an SS-34 head).· Ten volumes of cold 40 mM Tris was added to the pel-
let of washed cells, and the cells were allowed to swell in the cold 
for 3 min. The cells were centrifuged at 1446 g·min (2000 rpm x 3 min), 
lC volumes of 1 mM ZnCl2 was added to the pellet, mixed and allowed to 
stand at room temperature for 15 min. The mixture was then placed in 
ice for an additional 15 min. The zn++ treated cells were centrifuged 
at 210 g•min (750 rpm x 3 min in an SS-34 head). Ten ml of 40 mM Tris 
was added to the pellet and the protein concentration determined. The 
cells were divided for injection and the immunization scheme de-
scribed was followed. One week after the last injection, all mice were 
challenged with live SA-180 cells. One month following the initial 
challenge, the survivors were rechallenged with viable SA-180 cells. 
32 
In immunizations 1 and 4 with zn++ treated whole SA-180 cells, the 
modified cells were not frozen before the first injection was given, 
whereas in immunizations 2, 3 and'5 with zn++ whole cells, the first 
injection was frozen before administered. In all immunizations with 
zn++ treated SA-180 tumor cells, the 5 subsequent injections were froz-
en before injected. For group 1, the challenge given to all animals 
was 1 x 104 live SA-180 cells per animal. The rechallenge for the 
survivors was l'x 106 cells per animal. In group 2, the challenge was 
1.3 x 105 cells per animal. In group 3, the challenge was 1 x 105 
cells per animal, and in groups 4 and 5 the challenge was 1.1 x 105 
viable SA-180 cells per animal. 
Immunization with Whole Irradiated SA-180 Cells 
Whole SA-180 cells, harvested from HaM/ICR mice were washed and 
resuspended in HBS to a final concentration of 1 x 107 cells per ml. 
The cell suspension (10 ml) was placed into Falcon culture dishes and 
the open dishes were irradiated with U. V. light for 30 min at 50 rad/ 
min (1500 rads total). The cells were stored 1 m1 per tube (1 x 107 
cells) in the freezer and were used to immunize mice. Each mouse in 
the immunized group received 106 irradiated cells in each of the 6 i.p. 
injections, with a total of 6 x 106 cells administered pe~ animal. The 
control group received equal volumes of HBS. All mice were challenged 
with 1 x 106 viable SA-180 cells per mouse 1 week after the last injec-
tion. 
Immunization with Mitomycin C Treated 
SA-180 Cells 
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For one experiment, SA-180 tumor cells were treated with mitomycin 
C and then used to immunize mice. The SA-180 cells (4 x 107) were put 
into 3 ml of medium 199 (Difco) and 10% calf serum, 500 ug of mitomycin 
C was added and the cell suspension allowed to incubate for 45 min in a 
37° C water bath. At the end of the designated time, the cells were 
washed by centrifugation at 210 g·min (750 rpm x 3 min in an SS-34 head) 
three times in 5 mM EDTA and 0.9% NaCl, and the cells suspended in 10 
ml of PBS pH 7.4. They were stored in the refrigerator for less than 10 
days. Treated cells (1 x 105) were injected into a group of ten mice 
in the immunized group twice per week, while the 10 control mice were 
injected with an equal volume of HBS. All mice were challenged with 1 
x 105 viable SA-180 cells one week after the last injection of the mito-
mycin C treated cells. 
Immunotherapy Trials 
Two schemes with 20 mice each were used in an attempt to find the 
level of SA-180 zn++ two-phase stabilized membrane antigen that would 
most effectively enhance an immune .response to a preadministered dose 
of live SA-180 cells. 
ImmunotherapY Scheme 1 
Twenty mice were given a live SA-180 tumor cell injection of 2.5 
x 102 cells. Immunizations with SA-180 zn++ two-phase stabilized mem-
branes were started 24 hours later for the group to be immunized, where-
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as the control group received equal volumes .of HBS. The immunization 
scheme followed the general immunization scheme already described and 
the survival times of the mice were noted. 
ImmunotherapY Scheme 2 
Twenty mice were given an injection of 1 x 102 viable SA-180 cells. 
Immunizations with SA-180 zn++ two-phase stabilized membranes were start~ 
ed 24 hours later for the group to be immuniz~d, and the control group 
received equal volumes of HBS. The injection scheme used followed the 




Plasma Membrane Purification 
The isolation of plasma membranes from the Sarcoma-180 ascites 
tumor was based on a stabilization of the cell membrane by the divalent 
metal ion Zn++ followed by gentle homogenization to yield large frag-
ments of plasma membranes of reasonable purity. 
Immunization of C~l Mice with Zn++ Treated 
SA-180 Cell Membranes Isolated from Tumor 
Cells Grown in BDF1 Mice 
This experiment was designed to see if membranes isolated from 
SA-180 tumor cells grown in the inbred BDF1 mouse strain would immunize 
mice of the outbred CD1 strain. 
. A 8 ++ S~nce the S -1 0 Zn treated mem-
branes isolated from cells grown in BDF1 mice had been unable to immun-
ize the BDF1 mice against the tumor, either different antigens were 
expressed by the tumor when growing in the BDF1 mice, or there was a 
difference in the capability of the BDF1 's immune system. 
The results of this experiment are shown in Figure 3 and Table III. 
Of the immunized animals, 100% survived the challenge dose of 1.1 x 104 
viable SA-180 tumor cells. 
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Figure 3. Per Cent of Animals Surviving Following Injection of 1.1 
x 104 Viable SA-180 Cells in the Immunization Scheme 
Using BDF1 Grown zn++ Treated SA-180 Membranes to Immu-
nize CD1 Mice 
Group (a) was the control group and received injections of HBS. 
The immunized Group (b) received ZnC12 treated SA-180 membranes. All 
animals were challenged with 1 x 104 viable SA-180 cells on day 0. 
Survivors of the challenge were rechallenged on day 31 with 1.25 x 
105 live SA-180 cells per animal. Survivors of this were rechallenged 
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On November 20, 1975 all mice were challenged with 1.1 x 104 
viable SA-180 cells per animal. The MST (Mean Survival Time) for the 
control mice was 20.8 days after the challenge. One hundred per cent 
of the immunized mice survived the challenge and on 12-21-75 they were 
rechallenged with 1.25 x 105 viable SA-180 cells. Twenty-eight and 
one-half per cent (2 mice) from the immunized mice died but 71% sur-
vived the rechallenge. The 5 survivors were rechallenged with l x 105 
viable SA-180 cells on 4-5-76. Twenty-eight and one-half per cent 
( 2 mice) died with a MST of 19.5 days. Hmrever 43% of the original 7 
mice were able to neutralize all of the tumor dose administered 5 
months since their immunization. 
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In Figure 3 the per cent surviving in each group versus the time 
in day after tumor ceil injection is portrayed. Table III is a summary 
of the injection sch~me and challenges, and shows that 100% of the 7 
mice in the immunized group were able to neutralize all of the 1.1 x 104 
_I 
live SA-180 tumor cells in the challenging dose. All of the mice in the 
control group died, with a mean survival time (MST) of 20.8 days. 
Thirty-one days after the challenge, the survivors of the immunized 
group were rechallenged with 1.25 x 105 viable SA-180 cells. Twenty-
eight and one-half per cent (2 mice) of the original 7 mice died with a 
MST of 17 days, but 71% survived the rechallenge. The 5 survivors were 
rechallenged with 1 x 105 live SA-180 cells 4 months after the second 
rechallenge, and although it had been over 5 months since their immun-
ization, 43% (3 mice) of the original 7 mice were able to neutralize all 
of the tumor dose administered. Those that died had a MST of 19.5 days 
after the challenge. 
Immunization with Zn++ Stabilized SA-180 
Plasma Membranes Extracted with Glycine-




Another experiment involved modifying Zn two-phase membrane 
sheets with EDTA. In this type of procedure, small membrane vesicles 
are formed without the high-molecular-weight proteins that stabilize 
the membranes. 
. . ++ 
Stab1l1ze membranes are the products of Zn or other 
divalent metal treated SA-180 membrane isolations. Unstabilized mem-
branes are the products of a microsomal type isolation or are stabili~d 
membranes that have been EDTA-extracted. In stabilized. membranes, 
antigenic conformation and distribution are thought to be.locked into 
place, or are not free to move. In unstabilized membranes, antigenic 
conformation and distribution are presumed to be free to move. An 
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attempt was made to elucidate the effect on immunogenicity of the mem-
brane sheets that removal of these high-molecular-weight proteins had. 
Immunization with EDTA-Extracted Membranes 
Group 1 
The results in Figure 4 and Table IV show that 80% of the animals 
immunized with EDTA-extracted membranes were able to effectively resist 
a challenge of 1 x 104 viable SA-180 tumor cells. The control mice were 
all dead 19.5 days after tumor cell injection. The 2 immunized mice 
that died had a MST of 18.5 days. One month after the initialchaTienge, 
7 of the 8 survivors were rechallenged with 1 x 106 live SA-180 tumor 
cells, and all died with a MST of 20 days. The one mouse which had not 
been rechallenged with the other immunized mice was injected with 1 x 
105 viable SA-180 cells (rather than 1 x 106 cells) 3 months after the 
immunization and survived. This could indicate that it was the large 
rechallenging dose of 1 x 106 tumor cells for the rest of the immunized 
animals that had overwhelmed the animals immune system rather than an 
effect on long term immunity that removal of the high-molecular~weight 
proteins had. Since 106 tumor cells is a rather large challenge, even 
for some completely immunized animals to neutralize (8), the experiment 
was repeated and the challenge and rechallenge were kept at about 105 
viable SA-180 tumor cells. 
Figure 4. Per Cent of Animals Surviving Following Injection of l 
x 104 Viable SA-180 Cells in the Immunization Scheme 
Using EDTA-Extracted zn++ Treated SA-180 Membranes to 
Immunize Mice (Group l) 
Group (a) was the control group, and received injections of HBS. 
Group (b) received ZnCl2 treated SA-180 membranes that had been 
extracted with EDTA-glycine. All animals were challenged with l x 
104 viable SA-180 cells on day 0. All but one survivor was rechal-
lenged with 1 x 106 live SA-180 cells on day 30. On day 90, the one 
mouse that had not been rechallenged was injected with l x 105 viable 
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On January 5, 1976, all mice were challenged with 1 x 104 viable 
SA-180 cells. All of the control group died with a MST of 19.5 days 
after tumor cell injection. Eighty per cent of the immunized mice 
survived the challenge (2 died with a MST of 18.5 days) and 7 of the 
8 survivors were rechallenged with 1 x 106 cells on February 11. All 
mice rechallenged died with a MST of 20 days. The one mouse which 
had not been rechallenged with the rest was rechallenged with 1 x 105 
viable SA-180 cells on 4-5-76 and survived the challenge. 
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Immunization with EDTA-Extracted Membranes 
Group 2 
44 
The results in Figure 5 and Table V confirm that the glycine-EDTA 
extracted membranes will effectively immunize mice, with 88% of the 
immunized mice surviving a 1 x 105 viable SA-180 tumor cell challenge 
per mouse. Tte one mouse in the immunized group that died had a MST of 
22 days. All control mice died with a MST of 17.7 days. The survivors 
in the immunized group were rechallenged with 1 x 105 live SA-180 cells 
per animal one month after the initial challenge. All mice were able 
to survive the rechallenge. 
Immunization with EDTA-Extracted Membranes 
Group 3 
In this immunization, membranes were used which had been extracted 
with glycine-EDTA solution in which 2, mercaptoethanol had been added. 
The results show in Figure 6 and Table VI that only 10% (1 mouse) in 
the immunized group was able to neutralize all of the live tumor chal-
lenge of 1.25 x 105 viable SA-180 cells per animal. The 9 immunized 
mice that died had a MST of 20.9 days. All control mice died with a 
MST of 18.5 days. The one immunized survivor was rechallenged with 
1.05 x 105 viable SA-180 cells one month after the initial challenge 
and survived. The results show that under these conditions and with 
the immunization scheme used, the glycine-EDTA-2, mercaptoethanol~ex­
tracted SA-180 Zn++ stabilized membranes failed to illicit a protective 
immune response following a live tumor challenge. 
Figure 5. Per Cent of Animals Surviving Following Injection of 1 
x 105 Viable SA-180 Cells in the Immunization Scheme 
Using EDTA-Extracted zn++ Treated SA-180 Membranes to 
Immunize Mice (Group 2) 
\ 
Group (a) was the control group and received injections of HBS. 
Group (b) received ZnCl2 treated SA-180 membranes that had been 
extracted with EDTA-glycine. All animals were challenged with 1 x 
105 viable SA-180 cells per animal on day 0. The survivors were 
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On May 25, 1976, all mice were challenged with l x 105 viable 
SA-180 cells. All .. mice in the control group died with a MST of 17.7 
days. In the immunized group, 88% (8 mice out of the 9) survived. 
The l mouse that died had a MST of 22.0 days. The mice were rechal-
lenged on day 33 with l x 105 viable SA-180 cells per animal and all 
were able to combat this dose. 
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Figure 6. Per Cent of Animals Surviving Following .Injection of 1 
x 105 Viable SA-180 Cells in the Immunization Scheme 
Using EDTA-Extracted zn++ Treated SA-180 Membranes to 
Immunize Mice (Group 3) 
Group (a) was the control group and received injections of HBS. 
Group (b) received ZnCl2 treated SA-180 cell membranes that had ~een 
extracted with EDTA-glycine-2, mercaptoethanol. All animals were 
challenged with 1. 25 x 105 viable SA-180 cells on day 0. 
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All mice were challenged on June 14, 1976, with l. 25 x 105 viable 
SA-180 cells per animal. The control mice all died with a MST of 18.5 
days. In the immunized group, 9 of the 10 mice died with a MST of 
20.9 days. One mouse (10% of the immunized group) was able to neutra-
lize all of the challenge dose. This mouse was rechallenged on July 16, 
1976, and survived. 
51 
Immunization with Whole zn++ Treated 
SA-180 Cells 
Immunization with Whole zn++ Treated SA-180 
Cells Group·l 
The results of the first immunization with whole zn++ treated 
SA-180 tumor cells are presented in Figure 7 and Table VII. Forty-five 
per cent of the immunized group neutralized all of the challenge dose 
of 1 x 104 viable SA-180 cells. The 5 immunized mice that died had a 
MST of 15 days, whereas the control mice had a MST of 14.8 days after 
tumor cell injection. The survivors of the first challenge were re-
challenged one month after the initial challenge with l x 106 viable 
tumor cells. The 2 mice that died has a MST of 16 days, but 20% ~2 
mice) were able to combat this dose. The large challenge of l x 106 
cells could have accounted for a higher rate of death than if 1 x 105 
cells had been used. As stated earlier, l x 106 tumor cells is a 
rather large tumor burden to clear, even for some fully immunized 
animals. In repeats of this experiment the rechallenge was held at 
1 x 105 cells per animal. Almost 3 months after the initial challenge 
the 2 survivors were challenged with l x 105 live SA-180 cells and 
both were able to combat all of this tumor dose. 
The results show that zn++ treatment of the whole SA-180 tumor 
cells enhanced the whole cell's immunogenicity when the first injection 
was not frozen before use and following an injection scheme as de-
scribed. Even upon two challenges up to 4 months after immunization, 
20% of the animals survived. This indicates that the whole zn++ 
treated cells appear to be capable of illiciting a long term immune 
Figure 7. Per Cent of Animals Surviving Following Injection of 1 
x 104 Viable SA-18o~cells in the Immunization Scheme 
Using Whole zn++ Treated SA-180 Cells to Immunize Mice 
(Group 1) 
Group (a) was the control group and received HBS. Group (b) 
receiv4d ZnCl2 treated whole cells. All animals were challenged with 
1 x 10 viable SA-180 cells on day 0. On day 32, the survivors were 
rechallenged with l x 106 viable SA-180 tumor cells per animal. The 
survivors of this trial were again rechallenged and were given l x 
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On January 11, 1976, all mice were challenged with 1 x 104 viable 
SA-180 tumor cells per animal. The control group had a MST of 14.8 
days after tumor cell injection. Of the 9 immunized mice, 5 died with 
a MST of 15 days. There were 4 mice that survived, and they were 
rechallenged one month after the initial challenge (2-ll-76) with 1 x 
106 live SA-180 tumor cells per animal. The MST for the 2 mice that 
died was 17.5 days. The 2 mice that survived were rechallenged with 
l x 105 viable cells per animal almost 3 months after the initial 
challenge (4-5-76) and both mice survived. 
response. It is possible that zn++ treatment of the whole cells pro-
duces a different cell surface. 
'Immunization with Whole zn++ Treated SA-180 
Cells Group 2 
55 
The results of this immunization with whole zn++ treated SA-180 
cells, with all injections frozen before administered, are shown in 
Figure 8 and Table VIII. In this immunization, all mice in the immu-
nized group received a first injection of 4 mg whole zn++ treated cell 
protein rather than 0.4 mg per mouse. The control group had a MST of 
18.2 days, whereas the immunized group had a MST of 18.1 days after a 
live SA-180 cell challenge of l. 3 x 105 cells per animal. The 10 times 
more antigen presented in the first injection made a total of 8.0 mg 
whole cell protein administered in the immunization scheme.as compared 
to the 4.4 mg total protein of whole zn++ treated cells presented to 
the animals in immunizations 1, 3, 4 and 5 with zn++ treated whole 
cells. 
The higher amount of antigen presented to the animals in this 
immunization could have blocked the immune response by paralyzing the 
anirnaJ's immune system and allowing normal tumor growth. The results 
show that under these conditions (with 8.0 mg protein given) and with 
all injections frozen before administered, the zn++ treated whole SA-
180 cells failed to illicit a protective immune response after live 
tumor challenge. 
I 
Figure 8. Per Cent of Animals Surviving Following Injection of 1.3 
x 105 Viable SA-180 Cells in the Immunization Scheme 
Using Whole zn++ Treated SA-180 Cells to Immunize Mice 
(Group 2) 
Group (a) was the control group and received injections of HBS. 
Group (b) received ZnC12 treated whole SA-180 cells. All animals 
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On May 2, 1976, all mice were challenged with 1.3 x 105 cells per 
animal. The MST for the control mice was 18.2 days. The MST for the 
immunized mice was 18.1 days. 
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Immunization with Whole zn++ Treated SA-180 
Cells Group 3 
The results of this immunization, with all injections of zn++ 
I 
treated SA-180 cells frozen before administered, are shown in Figure 9 
and Table IX. All mice were challenged with 1 x 105 viable SA-180 
cells per animal. The immunize,d mice all died with a MS.T of 21.8 days, 
whereas all control mice died with a MST of 20.6 days. The results 
indicate that under these conditions and using the general immunization 
scheme already described, the zn++ treated whole SA-180 cells did not 
illicit a protective immune response against a live tumor challenge. 
Immunization with Whole zn++ Treated SA-180 
Cells Group 4 
The results of this immunization, with the first injection of zn++ 
treated SA-180 cells not frozen before administered and all subsequent 
injections frozen, are shown in Figure 10 and Table X. All mice were 
challenged with 1.1 x 105 viable SA-180 cells per animal. The immu-
nized mice that died (6 out of the 8 mice) did so before the challenge 
was given (using the challenge date as day 0, the mice died at a cal-
culated average MST of -4.3 days). There were 2 survivors that were 
able to combat the challenge dose. The control mice all died with a 
MST of 19.5 days. The results show that the zn++ treated whole SA-180 
cells, when given under these conditions, were effectively able to 
immunize mice against a live tumor challenge. 
I 
Figure 9. Per Cent of Animals Surviving Following Injection of 1 x 
105 Viable SA-180 Cells in the Immunization Scheme Using 
Whole zn++ Treated SA-180 Cells to Immunize Mice (Group 3) 
Group (a) was the control group and received injections of HBS. 
Group (b) received ZnC12 treated whole SA-180 cells. All animals 
were challenged with 1 x 105 viable SA-180 cells on day 0. 
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On June 16, 1976, all mice were challenged with 1 x 105 viable 
SA-180 cells per animal. All mice in the immunized group died with a 
MST of 21.8 days. All mice in the control group died with a MST of 
20.6 days. 
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Figure 10. Per Cent of Animals Surviving Following Injection of 1.1 
x 105 Viable SA-180 Cells in the Immunization Scheme 
Using Whole zn++ Treated SA-180 Cells to Immunize Mice 
(Group 4) 
Group (a) was the control group and received injections of HBS. 
Group (b) received ZnC12 treated whole SA-180 cells. All animals 
were challenged with 1.1 x 105 viable SA-180 cells per animal on day 
0. In Group (b), the mice that died (6 out of the 8) did so before 
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On August 4, 1976, all mice were challenged with 1.1 x 105 viable 
SA-180 cells per animal. All control mice died with a MST of 19.5 
days. In the immunized group there were 2 survivors (25%), while 75% 
(6 mice) died with a MST of -4.3 days. (These mice developed the tumor 
after the first injection was given in which some of the zn++ treated 
tumor cells were still viable since they were not frozen). 
Immunization with Whole zn++ Treated SA-180 
Cells Group 5 
66 
The results of this immunization, with all injections of zn++ 
treated SA-ltlO cells frozen before administered, are shown in Figure 11 
and Table XI. All mice were challenged with 1.1 x 105 viable SA-180 
cells per animal. The immunized mice that died (8 out of the 10) had a 
MST of 19 days, but 2 of the mice (20%) were able to survive the live 
tumor challenge. All control mice died with a MST of 19.5 days. The 
results show that under these conditions, the zn++ treated whole SA-180 
cells were able to effectively immunize mice. 
Immunization with Irradiated 
Whole SA-180 Cells 
The results of the immunization with whole irradiated SA-180 tumor 
cells are shown in Figure 12 and Table XII. The control mice had a 
MST of 12.3 days, while the immunized mice had a MST of 14.6 days 
after injection of 1 x 106 viable SA-180 cells per animal. In this 
tumor system, the 2.3 day lengthened survival time of the test mice is 
not meaningful. 
Immunization with Mitomycin C 
Treated Whole SA-180 Cells 
The results of the immunization with mitomycin C treated whole 
SA-180 cells are summarized in Figure 13 and Table XIII. The control 
mice and the immunized mice both had a MST of 18.5 days after a 1 x 
105 viable SA-180 tumor cell challenge per animal. The results 
Figure 11. Per Cent of Animals Surviving Following Injection of 1.1 
x 105 Viable SA-180 Cells in the Immunization Scheme 
Using Whole zn++ Treated SA-180 Cells to Immunize Mice 
(Group 5) 
Group (a) was the control group and received injections of HBS. 
Group (b) received ZnC12 treated whole SA-180 cells. All animals 
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On August 4, 1976, all mice were challenged with 1.1 x 105 viable 
SA-180 cells per animal. All control mice died with a MST of 19.5 
days. In the immunized ,group, the 8 out of 10 mice that died had a 
MST of 19 days. Two of the mice were able to combat the challenge 
dose and survived. 
Figure 12. Per Cent of Animals Surviving Following Injection of 1 
x 106 Viable SA-180 Cells in the Immunization Scheme 
Using Whole Irradiated SA-180 Cells to Immunize Mice 
Group (a) was the control group and received injections of HBS. 
Group (b) received whole SA-180 cel~s that had been irradiated. All 







6 6 6 
00 <D ~ 






































Irradiated Cells/Animal) (HBS) 






On October 6, 1975, all mice were challenged with 106 viable SA-
180 cells per animal. The control mice had a MST of 12.3 days. The 
immunized mice had a MST of 14.6 days. 
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Figure 13. Per Cent of Animals Surviving Following Injection of 1 
x 105 Viable SA-180 Cells in the Immunization Scheme 
Using Whole Mitomycin C Treated SA-180 Cells to Immu-
nize Mice 
Group (a) was the control group and received HBS. Group (b) 
received whole mitomycin C treated SA-180 cells. All animals were 
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All mice were challenged on July 31, 1975 with l x 105 viable 
SA-180 cells. Both control and immunized mice had a MST of 18.5 days. 
indicate that the whole mitomycin C treated SA-180 cells did not 
stimulate a protective immune response with the injection scheme used. 
Immunotherapy Trials 
Immunotherapy Scheme l 
The results of the first immunotherapy trial are shown in Figure 
14 and Table XIV. The control mice had a MST of 22.0 days after the 
time of injection of 2.5 x 102 viable SA-180 tumor cells. The immu-
nized mice had a MST of 23.25 days after tumdr cell injection. The 
immunization scheme used, with the injections of zn++ treated SA-180 
membranes beginning 24 hours after the injection of the tumor cells, 
did not aid the animals in combating the tumor challenge. 
Immunotherapy Scheme 2 
The second immunotherapy results are summarized in Figure 15 and 
Table XV. The control group outlived the immunized group, and it is 
possible that the higher amolli~t of antigenic stimulus presented to the 
immunized group during the immunizations could have blocked the immune 
response by paralyzing the animal's immune system. Other experiments 
are needed to draw any conclusions except that under these conditions, 
with the immunizations with zn++ treated SA-180 plasma membranes begin-
ning 24 hours after a viable dose of l x 102 SA-180 tumor cells, the 
immunized mice died sooner than the control mice. The test mice had a 
MST of 33.1 days after the live tumor cell injection, and the control 
group had a MST of 37.9 days. The lengthened survival time of this 
group of immunized mice over group l's immunized mice is apparently 
Figure 14. Per Cent of Animals Surviving Following Injection of 2.5 
x 102 Viable SA-180 Cells, with Immunotherapy with zn++ 
Treated SA-180 Membranes Beginning 24 Hours After Tumor 
Cell Injection (Immunotherapy Group 1) 
A pre-administered dose of 2.5 x 102 viable SA-180 cells was 
given to all animals on day 0. The immunized group (b) started 
immunotherapy with ZnC12 treated SA-180 membranes 24 hours later. 
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On February 11, 1976, all mice were injected with 2.5 x 102. 
Immunotherapy with zn++ treated SA-180 membranes began 24 hours later 
for the immunized group. Injection of HBS were given to the control 
mice. The control mice had a MST of 22.0 days after tumor injection, 
whereas the immunized mice had a MST of 23.25 days. 
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Figure 15. Per Cent of Animals Surviving Following Injection of 2.0 
x 102 Viable SA-180 Cells, with Immunotherapy with zn++ 
Treated SA-180 Membranes Beginning 24 Hours after Tumor 
Cell Injection (Immunotherapy Group 2) 
A pre-administered dose of 2.0 x 102 viable SA-180 cells was 
given to all animals on day 0. The immunized group (b) started 
immunotherapy with ZnCl2 treated SA-180 membranes 24 hours later. 
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On February 18, 1976, all animals were injected with 1 x 102 
viable SA-180 cells per animal. For the immunized group, immunizations 
with zn++ treated SA-180 membranes began 24 hours later. The control 
group received injections of HBS. The control group had a MST of 
37.9 days and the immunized group had a MST of 33.1 days. 
from the ~~ times lower pre-administered live tumor dose presented 
to this group. 
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 
The results summarized in Figures 16 and 17 show that SA-180 tumor 
cell membranes and various modified whole tumor cells can effectively 
immunize CD1 mice against homologous tumor with the injection scheme 
used. 
The results of the work done in this study with the BDF1 mouse-
SA-180 tumor cell system verified the immunizing potential of zn++ 
treated SA-180 membrane sheets. Membrane sheets were isolated from 
tumor cells grown in BDF1 mice and used to immunize CD1 mice. All 
(100%) of the immunized group were able to neutralize all of the 
initial challenge dose of viable tumor cells, so it is evident that 
membranes isolated from the BDF1 mice could satisfactorily immunize 
mice of another strain (CD1 ). This indicates that the tumor must 
express much the same antigenic configuration while growing in the 
BDF1 as it does growing in the CD1 mice. Therefore, I conclude that 
there appears to be a difference in the immune capability of the BDF1 
mice that will not allow immunity to develop against a live tumor 
challenge after immunization with the SA-180 tumor cell membranes. 
These findings agree with the work done by Mullins (42) and co-
workers in which attempts were made to immunize inbred BDF1 mice with 
ZnC12 treated SA-180 membranes. One group was challenged with viable 
SA-180 cells, and one group was challenged with viable Ll210 tumor 
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Figure 16. Per Cent of Animals Surviving Following Live Tumor Chal-
lenge in Immunizations and Immunotherapy with ZnC12 
SA-180 Membranes 
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Figure 17. Per Cent of Animals Surviving Following Live Tumor Chal-
lenge in Immunizations with Whole SA-180 Modified Cells 
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cells as a check for the specificity of the immune response elicited 
by immunization with SA-180 membranes. No lengthening of survival time 
was seen in either group (42). 
Preliminary work (Huggins, Mullins, and co-workers) (27, 42) with 
SA-180 tumor cells was important in interpreting results of the 
immunization schemes in CD1 mice. In order to detect any improvement 
in the survival capabilities of the host CD1 mice as a result of 
immunization, it was first important to understand the normal tumor-
host interaction (27, 42). Different groups of CD1 mice were admin-
istered doses of l x 102 through l x 107 viable SA-180 cells per animal 
by i.p. injections and the survival time of the mice noted to deter-
mine the MST of unimmunized mice. From these data, any lengthened 
survival time due to immunizations with modified tumor material could 
be recognized. 
Figure 18 shows the per cent cumulative mortality for each inocu-
lation group plotted against the time of death after inoculation. 
Because the host in these studies was from outbred stock, the distri-
bution of deaths within each challenge group is greater than that 
generally observed for inbred strains (27, 42). 
From the cumulative mortality data (27), a diagram plotting the 
mean survival time as a function of the cell inoculum concentrations 
was constructed (Figure 19). The results show that the mean survival 
time for the CD1 host is a linear function of the inoculation density 
and, therefore, a good measure of the effects of immunization on tumor 
survival. The approximately 20 hours deviation in mean survival time 
resulting from a 102 tumor cell inoculation may result from the efforts 
of the host in combating tumor challenge by a small tumor burden. 
Figure 18. Cumulative Mortality of HaM/ICR (CDl) Mice Following 
Injection of Different Cell Concentrations of SA-180 
Seven groups of 15 mice each were challenged with viable SA-180 
at concentrations of 1 x 102 through 1 x 108 cells. The number of 
animals dead from each group plotted as the per cent cumulative 
mortality is shown as a function of time following the tumor chal-
lenge. 
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Figure 19. Tumor Cell Inoculation Concentration as a Function of the 
Host Mean Survival Time 
Data derived from the Dose-Response experiment in which each 
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The results of this study agreed with earlier experiments by 
others that were conducted and confirmed that the immunizing potential, 
i.e. those tumor-associated antigens which are capable of eliciting an 
effective anti-SA-180 immune response, were retained in an active, con-
formation on the isolated plasma membrane (27). 
To further substantiate the anti-cancer immunizing potential of 
the isolated SA-180 plasma membranes, other immunization experiments 
were performed which involved additional controls as well as a test 
group receiving SA-180 plasma membranes (27). The different control 
groups received saline, HBS, human erythrocyte membranes from rbc types 
A, B, or 0, HaM/ICR (CD1 ) mouse erythrocyte membranes, or washed sus-
pensions of in vitro grown fetal mouse cells, with the immunization 
scheme described in Chapter II. None of the control mice were afforded 
protection against a live tumor challenge, yet 70% of the SA-180 tumor 
cell membrane immunized animals survived the challenge. 
These findings established that isolated SA-180 plasma membranes 
can be effective immunizing agents against homologous tumor. The 
administration of non-tumor membranes or in vitro grown fetal mouse 
cells showed no stimulation of the host's immune system in combating 
tumor challenge. Tumor cell membranes did enhance the survival time of 
the host and in many cases caused complete elimination of the challenge 
dose. This indicates the reaction of the host to the SA-180 tumor 
material results in a specific immune stimulation and not a non-specific 
response as with BCG (27). 
A titration of antigenic material in relation to the immune re-
sponse was conducted, in which smaller doses of membrane material were 
given while trying to maintain maximal results (42). It was found that 
95 
comparable results were not obtained when the level of antigenic 
material was lowered to one-half the standard dose or lower, and for 
that reason the level used in this study was kept at the standard 
dose. The standard dose referred to is 0.4 mg for the first injection 
and 0.8 mg for the 5 remaining- injections. 
These results strongly suggest that the isolated plasma membrane 
exhibits antigens accessible to the immune system of the host that are 
also cross-reactive with the viable tumor cell. 
Further studies were conducted to determine the effectiveness of 
immunizations with SA-180 plasma membranes with injections of membranes 
given twice a week for 3 weeks with a total of 4.4 mg membrane protein 
given per mouse (0.4 mg for the first injection and 0.8 mg given for 
the 5 subsequent injections) against challenges of different numbers 
of viable SA-180 tumor cells (102 through 105 (17) and 104 through 107 
(42)). 
The results indicate that under these conditions, with the chal-
lenge given 1 week after the last immunization, the immune system of 
the host is relatively successful in eradicating tumor doses of 104 
cells or smaller, but is less successful when the tumor burden reaches 
107 cells (27, 42, 13). These findings are in general agreement with 
experiments using other tumor-host systems which show that the limits 
of tumor burden for successful immunotherapy are quite low (29, 26). 
When the challenge was given 3 days after the last immunization (13), 
there was a 20% lower survival rate at a 104 live tumor cell challenge. 
This could indicate that the immune system requires an extra 4 days to 
better combat the challenge dose. 
In this study, immunization with whole irradiated SA-180 cells, or 
SA-180 cells that had been treated with mitomycin C, when administered 
under conditions given in Chapter II, has shown that the whole SA-180 
cell was not immunogenic when rendered non-viable by these agents. 
However, treatment of whole SA-180 cells with ZnC12 enhanced the whole 
cell's immunogenicity, with 45% of the immunized animals able to 
neutralize all of the 1 x 104 viable tumor cell challenge in irnmuni-
zation 1 with whole zn++ treated SA-180 cells. The first injection of 
the series in this immunization was not frozen before administered. 
Two of these survivors were able to combat a rechallenge dose of 1 x 
106 viable SA-180 cells. As mentioned in Chapter III, it is possible 
that the zn++ treatment helps maintain the antigenic distribution of 
the cell membrane. 
In immunizations 2, 3 and 5 with ZnC12 treated SA-180 cells, all 
injections were frozen before administered. In immunization 2, the 
animals were given a first injection of ten times more whole cell 
protein than given in the first injection of all other immunizations. 
In immunization 4, like in immunization 1, the first injection was not 
frozen before administered, yet all subsequent injections were frozen. 
Since no mice in the immunized group in immunization 3 with zn++ 
treated SA-180 cells were able to combat the challenge dose of 1 x 105 
viable SA-180 cells, a repeat of the procedure (not freezing the zn++ 
treated cells before giving the first injection) that was used in 
immunization 1 with zn++ whole cells (in which there was 45% survival) 
was performed in immunization 4 in an attempt to see if the difference 
in imm~ity obtained between the two methods was due to the first 
injection not being frozen before administered. 
\ 
In immunization 4 (first injection not frozen before administered), 
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there were 2 survivors out of the 8 mice (25% survival) after a 1.1 x 
105 viable SA-180 tumor cell challenge. The 6 immunized mice that died 
had a MST of -4.3 days since all of the mice that died did so before 
the challenge was given (day 0) due to proliferation of some of the 
tumor cells in the first injection which had not been killed by zn++ 
treatment (and were usually killed by freezing). All control mice died 
with a MST of 19.5 days. The reason for the lower survival rate in the 
immunized mice th~n in immunization l can possibly be accounted for by 
the fact that in immunization l a ten times lower live tumor challenge 
was given (l x 104 SA-180 cells). 
In immunization 5 with zn++ treated whole SA-180 cells, there were 
also 2 survivors (20% survivors, since there were 10 mice in this 
trial). This scheme was set up so that all injections were frozen 
before administered, so it appears that there is no difference in 
immunizing potential between frozen and non-frozen whole ZnCl2 treated 
SA-180 cells. The immunized mice that did die had a MST of 19 days, 
whereas all control mice died with a MST of 19.5 days. It appears, 
then, that the mice in the immunization 3 with zn++ whole cells died 
possibly because smaller-sized mice were used or to a difference in 
tumor cell viability rather than to an effect attributable to the cells 
having been frozen before administered. 
Extraction of the high-molecular-weight proteins from the zn++ 
treated SA-180 membrane sheets with glycine-EDTA did not decrease their 
immunizing potential against the initial live tumor challenge. When 
the high-molecular-weight proteins are extracted with EDTA, the SA-180 
membrane changes shape, becoming small membrane vesicles. The corre-
lation between the disappearance of the high-molecular-weight proteins 
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and the shape change of the SA-180 membrane lends support to the 
possibility that these proteins were involved in maintaining the shape 
of the cell (27). That it is the high-molecular-weight proteins that 
are being extracted with EDTA is a problem a colleague is attempting to 
solve by work with gel electrophoresis. The high-molecular-weight 
proteins are only found associated with the plasma membrane under 
certain conditions, which would yield whole envelopes or very large 
sheets of plasma membranes (27). The use of zn++ allowed isolation of 
the proteins with the membrane in a form where a large percentage could 
be extracted by low ionic strength buffers (27). 
In one immunization with EDTA-glycine-extracted SA-180 membranes, 
80% of the immunized animals were able to combat the initial challenge 
of viable SA-180 cells. In another group, 88% of the immunized animals 
were able to combat the initial challenge of live tumor. However, in 
the third EDTA-glycine extraction, 2, mercaptoethanol was added. If 
proteins on the membrane are held together by disulfide bonds, the 2, 
mercaptoethanol will disrupt the bond and allow the protein to open up. 
Since only 10% (1 mouse) was able to survive a challenge of 1.25 x 105 
viable SA-180 cells per animal, it appears the extraction result was 
not the same immunogenically as in immunizations 1 and 2 with EDTA-
glycine-extracted membranes. The 1 survivor was able to combat a re-
challenge dose of 1.05 x 105 live SA-180 cells. 
The results of both immunotherapy trials (Groups 1 and 2) and of 
immunizations with both EDTA-extracted SA-180 membranes (Group 1) and 
zn++ treated whole SA-180 cells (Group 2) show the problem of trying 
to find and administer the level of antigenic stimulus that provides 
the host with the best immunologic protection without paralyzing the 
host's immune system. 
In experiment 2 with zn++ treated whole SA-180 cells, the immu-
nized animals received a first injection of 10 times more protein 
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(4.0 mg) than given in all other immunizations (0.4 mg). The subsequent 
5 injections were 0.8 mg protein. Upon a live tumor challenge, the 
immunized mice died sooner than control animals. The immunized mice 
had a MST of 18.1 days and control mice had a MST of 18.2 days. 
Upon a rechallenge of the first group in the immunization with 
EDTA-glycine-extracted membranes, all animals injected with 1 x 106 
viable cells died. The one mouse that had not been rechallenged was 
injected with 1 x 105 viable SA-180 cells and survived. The higher 
number of tumor cells in the rechallenge could have accounted for a 
higher rate of death. Since all mice in the second immunization with 
glycine-EDTA-extracted SA-180 membranes were able to survive a re-
challenge of 1.0 x 105 viable SA-180 cells, it appears that the higher 
number of cells in the rechallenge of the first immunization was the 
cause of the higher rate of death rather than an effect on long-term 
immunogenicity that removal of the high-molecular-weight proteins had. 
In these experiments, as in the immunotherapy trials, the level of 
antigenic stimulus given seemed to have been too high, and since in 
most of these cases, the control mice lived longer than the immunized 
animals, we can infer that the antigenic stimulus in the amount given 
interferred with,any immune reactions that took place when the non-
immunized animals were introduced to the tumor dose. In immunotherapy 
group 1, the immunized group died with a MST of 23.25 days, while con-
trol mice died with a MST of 22.0 days. In group 2, the immunized mice 
died with a MST of 33.1 days and the control mice died with a MST of 
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37.9 days. 
Since in the immunoprophylaxis immunizations, the test animals 
received amounts of membrane protein identical to the amount received 
in immunotherapy groups, the only difference noted between the 2 
methods is the time of live tumor injection and the size of the chal-
lenge dose. In immunoprophy~axis, the challenge of 1 x 105 cells (in 
most cases) was given 1 week after the last of the 6 immunizations. In 
both immunotherapy groups, a live tumor challenge of 1 x 102 viable 
SA-180 cells (Group 2) or 2.5 x 102 cells (Group 1) was given first and 
immunizations with zn++ treated SA-180 membranes were started 24 hours 
later. 
Perhaps the membrane immunizations coupled with the increasing 
tumor burden in immunotherapy trials as the tumor cells multiplied 
overwhelmed the immune system of the host. Since the immunized animals 
died sooner than the controls, it appears that the immune system in 
these cases were paralyzed by too much antigen. In all these experi-
ments, it seems the higher level of antigenic stimulus presented in 
each case went above the narrow zone under which no stimulation occurs 
and above which paralysis of the immune system develops ( 40). That 
the choice of the immunological response between paralysis and immunity 
can be controlled by antigen dosage was first noted by Glenny and 
Hopkins ( 1924) ( 40) . 
In summary, work done in this study correlates well to previous 
work done by Huggins (27), Mullins (42) and co-workers. Once it was 
verified that intact zn++ treated SA-180 membrane sheets were immuno-
genic, modifications of these membranes were performed in an attempt to 
elucidate the effect of the modification on the zn++ treated membrane's 
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immunogenicity. Although most of the immunizations with modified whole 
SA-180 cells were unsuccessful, it was found that ZnC12 treatment of 
the whole cell enhanced the whole SA-180 cell's immunogenicity, with 
45% of the immunized animals able to combat a live SA-180 tumor cell 
challenge of 1 x 104 cells per animal. It was also fourtd that extrac-
tion of the high~molecular-weight proteins with glycine-EDTA did not 
decrease the membrane's immunizing potential, and that immunizations 
with SA-180 membranes isolated from tumor cells grown in another strain 
of mice would successfully immunize CD1 mice. Furthermore, the result-
ing immunity has been shown to be the long-term type, lasting in some 
cases greater than 6 months. The use of combination immunotherapy with 
modified whole tumor cells or modified tumor cell membranes may facili-
tate the rejection of even greater numbers of tumor cells. Huggins and 
Chestnut expressed doubt that all tumor cells or membranes will be 
immunogenic in their native form (27, 13). Most likely they can be 
made antigenic and effective immunizing agents by enzymatic and/or 
chemical modifications (27, 13). 
In the isolation of tumor cell membranes for use in immunization 
for humans it must first be ascertained that the procedure does not 
concentrate any C-type membrane-~ssociated virus that could infect the 
host to which it is administered during immunoprophylaxis or immuno-
therapy. In the case of SA-180 cells, a search of the literature did 
not turn up any evidence of C-type virus~s associated with the SA-180 
cell. Although certain findings suggest that an RNA polymerase enzyme 
is present in SA-180 cells (which could indicate the presence of a 
virus), no evidence of a virus particle has been found in the litera-
ture. The success of the zn++ treated membrane as an effective 
immunizing agent in mice with no tumor development, lends support to 
the theory of the safety of this agent to the host. 
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The findings in this study verify that certain modifications of 
the SA-180 tumor cell or it's cell membrane prior to their use in 
immunoprophylaxis or immunotherapy can make them antigenic and effec-
tive immunizing agents. The evidence indicates that these agents may 
represent an important initial step towards the development of more 
effective tumor-specific immunotherapy and immunoprophylaxis agents. 
CHAPTER V 
SUMMARY 
It has been shown that plasma membranes isolated from SA-180 tumor 
cells by the method of Shin and Carraway can be administered to host 
CD1 mice on schedules and quantities to induce immunity against a 
viable tumor challenge. Certain further modifications of these isola-
ted membranes produced an immunogenic agent that allowed immunity to 
develop against a live tumor challenge following immunization with this 
agent. 
Whole SA-180 tumor cells were treated in fashions similar to 
procedures used for membrane treatment and these procedures enhanced 
the whole tumor cell's immunogenicity in some cases, allowing almost 
50% of the immunized mice to reject a live tumor challenge following 
immunization. 
It can be concluded from this study that modifications of SA-180 
tumor cells and tumor cell membranes can produce immunizing agents 
capable of inducing immunity against live SA-180 tumor cells. This 
study also represents a starting point for possible immunotherapy 
agents, if the times of administration of the tumor and initiation of 
the immunotherapy agents, as well as the dose of both live tumor and 
the immunotherapy agents are manipulated in such a way as to allow the 
host to develbp tumor immunity. 
It seems plausible that isolated tumor cell membranes and modified 
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whole tumor cells could be used in remission therapy of cancer patients. 
If after surgery tumor cells or membranes were isolated from directly 
removed cells or cultured cells, they could be modified and administered 
to the patient to induce immunity to eliminate any remaining cells at 
the primary, or possible metastatic sites. 
A SELECTED BIBLIOGRAPHY 
1. Angeletti, P. 1J., B. w. Moore, and V. Suntzeff. 1960. Similarity 
of proteins and enzymatic patterns in different types of 
malignant tissues. J. Nat. Cancer Insti t. 20: 1592-1597. 
2. Atkinson, P. , and I. A. Davis. 1974. Simple procedure for the 
preparation of Erlich Ascites cells for the induction of 
immunity. Experientia 30: 427-428. 
3. Barski, J. K., and D. LeFrancois. 1974. Kinetics of cell-mediated 
immune response in cancer-bearing hosts. Investigation and 
Stimulation of Immunity in Cancer Patients. Springer-Verlag, 
New York. 54-57. 
4. Bartlett, G. L., J. W. Kreider, and D. M. Purnell. 1976. Immuno-
therapy of cancer in animals: models or muddles. J. Nat. 
Cancer Instit. 56 (2): 207-210. 
5. Bradner, W. T., D. A. Clarke, and C. C. Stock. 1958. Stimulation 
of host defense against experimental cancer I. Zymosan and 
Sarcoma 180 in mice. J. Nat. Cancer Instit. 18: 347-351. 
6. Bekesi, J. G., G. Arneault, L. Walter, and J. G. Holland. 1972. 
7. 
Immunogenicity of leukemia Ll210 cells after neuraminidase 
treatment. J. Nat. Cancer Inst. 49: 107-118. 




W. B. Saunders Co., Philadel-
8. Benarcerraf, B. 1974. Summary of working session on the mechan-
ism of action of immunological adjuvants. Investigation and 
Stimulation of Immunity in Cancer Patients. Springer-Verlag, 
New York. 224-227. 
9. Benjamini, E., and R. T. Scinbienski. 1974. The preferential in-
duction of cell-mediated immunity and some preliminary 
observations on its application to tumor immunotherapy. In-
vesti ation and Stimulation of Immunit in Cancer Patients. 
Springer-Verlag, New.York. 07- l . 
10. Cantrell, J. L., J. J. Killion, and G. M. Kollmorgen. 1976. 
Correlations between humoral immunity and successful chemo-
therapy-immunotperapy. Cancer Res. 36: 3050-3059. 
105 
106 
11. Carraway, K. L., and B. C. Shin. 1972. Specific modification, 
isolation, and partial characterization of an erythrocyte 
membrane protein. J. Biol. Chern. 247: 2102-2108. 
12. Cerottine, J., and K. T. Brunner. 1974. Advances in Immunology. 
Academic Press, New York. 207. 
13. Chestnut, R. W., J. W. Huggins, J. A. Mullins, K. L. Carraway, and 
N. N. Durham., Anticancer immunization with plasma membranes. 
Department of Microbiology and Department of Biochemistry, 
Agricultural Experiment Station, Oklahoma State University, 
Stillwater, Oklahoma. 1975. 
14. Coggin, J. H., and N. G. Anderson. 1974. Cancer, differentiation 
and embryonic antigens: some central problems. Advances in 
Cancer Research. New York Academic Press 10: 105-165. 
15. Cohen, M. H. 1975. Lung cancer: a status report. J. Nat. 
Cancer Insti t . .2..2_ ( 3): 505. 
16. Colter, J. S., J. Kuhn, and K. A. 0. Ellemi. 1961. The ribonu-
cleases of mouse ascites tumors. Cancer Res. 21: 48. 
17. Davis, B. D., R. Dulbecco, H. Eisen, H. Ginsberg, W. B. Wood Jr., 
and M. McCarty. 1973. Microbiology. Harper & Row, Hagers-
town. 568-570. 
18. Durr, R. E., and B. A. Briody. l963. Interaction of vaccinia 
virus with the Ehrlich ascites carcinoma. Cancer Res. 23: 
157-159. 
19. Faraci, R. P., and L. Schour. 1974. Malignant melanoma: specific 
immunity induced by Bacillus Calmette-Guerin in BALB/C mice. 
Science 185: 68-69. 
20. Frost, P., and C. J. Sanders. 1975. Tumor immunoprophylaxis in 
mice using glutaraldehyde-treated syngenic tumor cells. 
Cancer Res. }2_: 2646-2650. 
21. Gutterman, J. U., G. Mayligit, Ch. M. McBride, E. Frei III, and E. 
M. Hersh. 1974. BCG stimulation of immune responsiveness 
in patients with malignant melanoma. Investigation and Stim-
ulation-of Immunity in Cancer Patients. Springer-Verlag, New 
York. 476-485. 
22. Heidelberger, M. 1973. Immunochemistry of bacterial polysaccha-
rides. Research in Immunochemistry and Immunobiology. 
University Park Press, Baltimore. 1-29. 
23. Hellstrom, K. E., and~. Hellstrom. 1970. Immunologic enhance-
ment as studied by cell culture techniques. Ann. Rev. 
Microbial. 24: 204. 
107 
24. Hellstrom, K. E., and I. Hellstrom. 1971. Advances in Immunology. 
Academic Press, New York. 209. 
25. Herberman, R. B. 1974. Advances in Cancer Research. Academic 
Press, New York. 207. 
26. Hersh, E. M., T. U. Gutterman, and G. Maulight. 1973. Immunology 
of Cancer in Man. C. C. Thomas, Springfield, Illinois. 
27. Huggins, J. W. "The Isolation, Characterization, and .utilization 
of Plasma Membranes from Tumor Cells". Ph.D. Thesis, Okla-
homa State University. 1975. 
28. Huggins, J. w., R. W. Chestnut, N. N. Durham, and K. L. Carraway. 
1975. Molecular changes in cell surface membranes resulting 
from trypsinization of Sarcoma 180 Tumor Cells. Oklahoma 
State University Departments of Biochemistry and Microbiology. 
Stillwater, Oklahoma. 
29. Kolsh, E., R. Menersen, and E. Diller. 1973. Low dose tolerance 
preventing tumor immunity. Europ. J. Cancer 2: 879-882. 
30. Koreman, S. G. 1975. Estrogen receptor assay in human breast 
cancer. J. Nat. Cancer Instit. 22 (3): 543. 
31. Mantonvani, A., A. Veechi, and F. Spreafico. 1975. The attacker: 
target-cell ratio and serum effects on in vitro cell-mediated 
immunity. J. Nat. Cancer Insti t. 22 ( 2): 483. 
32. Marcove, R. C. 1973. A clinical trial of autogeneous vaccines in 
the treatment of osteogenic Sarcoma. Investigation and Stim-
ulation of Immunity in Cancer Patients. Springer-Verlag, New 
York. 488-495. 
33. Mardiney, M. R., Jr., 1. Chess, G. N. Bock, P. C. Ungaro, and D. 
H. Buchholz. 1974. Immunologic effects of BCG in patients 
with malignant melanoma. Investigation and Stimulation of 
Immunity in Cancer Patients. Springer-Verlag, New York. 
426-433. 
34. Marx, J. L. 1974. Tumor Immunology (I): The host's response to 
cancer. Science 184: 552-556. 
35. Mathe, G., M. Kamel, M. Dexfulian, 0. Halli-Pannehko, and C. 
Bourat. 1973. Experimental screening for "systemic adju-
vants of immunity" applicable in cancer immunotherapy. 
Cancer Res. 3l: 1987-1997. 
36. Mathe, G., and R. Heiner. 1974. Recent Results in Cancer Research. 
Springer-Verlag, New York. 
37. McCollester, D. L. 1970. Isolation of Meth A cell surface mem-
branes possessing tumor specific transplantation antigen 
activity. Cancer Res. 30: 2832-2840. 
108 
38. Mitchison, N. A. 1968. The dosage requirements for immunological 
paralysis by soluble proteins. Immunology 15: 509-529~ 
39. Moller, G., and Erna Moller. 1975. Considerations of some 
current concepts in cancer research. J. Nat. Cancer Instit. 
55 (4): 755-759. 
40. Mullins, J. A. "Isolated Tumor Cell Membranes Used as Anti-Cancer 
Immunizing Agents". M. S. Thesis, Oklahoma State University. 
1975. 
41. Old, L. J., and E. A. Boyse. 1964. Immunology of experimental 
tumors. Ann. Rev. Med. 15: 167-186. 
42. Farant, M., and L. Chedid. 1974. Biological properties of non-
toxic water-soluble immunoadjuvants from mycobacterial cells. 
Investigation and Stimulation of Immunity in Cancer Patients. 
Springer-Verlag, New York. 190-195. 
43. Prager, M.D., I. Derr, A. Swann, and J. Cotropia. 1971. Immuni-
zation with chemically modified lymphoma cells. Cancer Res. 
31: 1488-1491. 
44. Prager, M.D., F. S. Baechtel, R. J. Ribble, C. M. Ludden, and J. 
46. 
M. Mehta. 1974. Immunological stimulation with modified 
lymphoma cells in a minimally responsive tumor-host system. 
Cancer Res. 34: 3203-3209. 
Prehn, R. T. 
growth. 
1972. The immune reaction as stimulator of tumor 
Science 176: 170-171. 
Richards, R. M., and J. M. Knowles. 
protein cross linking reagent. 
1968. Glutaraldehyde as a 
J. Mol. Biol. 37: 231-233. 
47. Roizman, B., and P. G. Spear. 1971. Herpesvirus antigens on cell 
membranes detected by centrifugation of membrane-antibody 
complexes. Science 171: 298-300. 
48. Rosenthal, S. R. 1974. BCG and the lympho-reticuloendothelial 
system. Investigation and Stimulation of Immunity in Cancer 
Patients. Springer-Verlag, New York. 228-238. 
Shin, B. C., and K. L. Carraway. 1973. 
of Sarcoma 180 Ascites tumor cells. 
330: 254-268. 
Cell surface constituents 
Biochim. Biophys. Acta 
50. Shipman, C. 1969·. P.S.E.B.M. 130: 305. ' 
51. Silagi, S., E. w. Newcomb, and M. E. Weksler. 1974. Relationship 
of antigenicity of melanoma cells grown in 5-Bromodeoxyuri-
.dine to reduced tumorigenicity. Cancer Res. 34: 100. 
109 
52. Simmons, R. L., and A. Rios. 1972. Immunospecific regression of 
Methylchdlanthrene fibrosarcoma using neuraminidase: (III). 
Synergistic effect of BCG and neuraminidase treated tumor 
cells. Ann. Surg. 176: 188-193. 
53. Simmons, R. b., A. Rios, L. Toledo-Pereyra, and D. Steinmiller. 
1975. Modifying the immunogenicity of cell membrane antigens; 
tumors and transplants. American Journal of Clinical Path-
ology 63 (5): 714-733. 
54. 
55. 
Sinkovics, J. G., H. Theta, H. D. Kay, K. 
C. D. Howe, and C. C. Shullenberger. 
of immune reactions by immunotherapy 
Sarcoma-specific reactions in vitro. 
137-149. 
K. Loh, D. E. Williams, 
1974. Intensification 
attempts at measuring 
Neoplasm Immunity. 
• 
Smith, A. G. 1964. 
nucleic acids. 
Cytologic and cytotoxic changes induced by 
Cancer Res. 24: 603. 
56. Stolfi, R. L., R. A. Fugmann, L. M. Stolfi, and D. S. Martin. 
1975. Development and inhibition of cytotoxic antibody 
against spontaneous murine breast cancer. J. Immunology 
114 (5): 1824-1830. 
57. Stewart, H. L., K. C. Snell, L. J. Dunham, and L. J. Schbyensin. 
1959. SA-180 Ascites Twnor Cells. Atlas of Tumor Pathology. 
Sec XII. Washington, D. C. 
58. Theilen, G. H., D. Gould, M. Foler, and D. L. Dungworth. 1971. 
C-type virus in tumor tissue of a woolly monkey with fibro-
sarcoma. J. Nat. Cancer Instit. 47: 881-889. 
59. Triplett, R. B., J. M. Wingate, and K. L. Carraway. 1974. Calcium 
effects on erythrocyte membrane proteins. Biochemical and 
Biophysical Research Communications 49 (4): 1014-1020. 
60. Twomey, P. T., W. J. Catalong, and P. B. Chretien. 1974. Cell~ 
immunity in cured cancer patients. Cancer 33 (2): 435-440. 
61. Villee, C. A., W. E. Walker, Jr., and F. E. Smith. 1968. General 
Zool. W. B. Saunders Co., Philadelphia. 
62. Weiss, L. 1973. Neuraminidase, sialic acids, and cell inter-
actions. J. Nat. Cancer Instit. 2Q (1): 3-18. 
63. Woodhour, K. , E. Jenson, and J. Warren. 1960. Development and 
application of new parenteral adjuvants. Biologics Research 
Dept., Chas. Pfizer and Co., Inc. Terre Haute, Indiana. 
64. Wester, A. D., A. L. Pailla, M. W. Taylor, and E. D. Weinbery. 
1975. zn++ suppression of initiation of SA-180 growth. 
J. Nat. Cancer Instit. 54 (2): 1000-1003. 
110 
65. Zbar, B. 1974. Specific and nonspecific immunotherapy: Use of 
BCG. Investigation and Stimulation of Immunity in Cancer 
Patients. Springer-Verlag, New York. 
VITA 
Nancy Jo Edmisten Neafus 
Candidate for the Degree of 
Master of Science 
Thesis: ISOLATED TUMOR CELL PLASMA MEMBRANES AND MODIFIED WHOLE TUMOR 
CELLS AS ANTICANCER IMMUNIZING AGENTS 
Major Field: Microbiology 
Biographical: 
Personal Data: Born in~lsa, Oklahoma, December 14, 1952, the 
daughter of Mr. an<f Mrs. E. D. Edmisten. 
Education: Graduated from Memorial High School, Tulsa, Oklahoma, 
in May, 1971; received Bachelor of Science degree in Micro-
biology from Oklahoma State University in May, 1975; completed 
requirements for the Master of Science degree at Oklahoma 
State University in December, 1976. 
Professional Experience: Research assistant, Department of Micro-
biology, Oklahoma State University, June, 1975 - December, 
1976. 
